AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Huntington's Disease

Recent research efforts aimed at curing Huntington's Disease.

Last updated

Huntington’s Disease

Overview

Huntington’s disease (HD) is a rare, inherited brain disorder caused by an expanded CAG DNA repeat in the HTT gene. It is autosomal dominant, meaning that a child of a person with the disease-causing variant has a 50% chance of inheriting it. The altered gene produces mutant huntingtin (mHTT), a protein that progressively damages brain cells, especially in movement-control and thinking-related regions. Symptoms commonly begin in adulthood and include involuntary movements (chorea), slowed thinking and planning, behavioral or psychiatric changes, and eventually loss of independence; the illness typically progresses over roughly 15–20 years after onset. Huntington Disease: GeneReviews

There is still no approved treatment that prevents, reverses, or reliably slows HD itself. Current care is multidisciplinary and symptom-focused: medicines such as tetrabenazine, deutetrabenazine, or valbenazine can reduce chorea, while psychiatric treatment, physical therapy, occupational therapy, speech therapy, nutrition support, and social-care planning address the broader effects of the disease. Huntington Disease: GeneReviews Mayo Clinic: Huntington’s disease diagnosis and treatment

Scope of Recent Research (2020–present)

Since 2020, HD research has become increasingly focused on treating the root biology rather than only symptoms: lowering mHTT, preventing further expansion of the disease-causing CAG repeat within vulnerable brain cells, and ultimately repairing or disabling the mutant gene while preserving normal huntingtin. The field now includes RNA medicines, oral RNA-splicing drugs, directly injected gene therapies, and early gene-editing programs; however, no approach has yet demonstrated that it cures HD in people. Huntington’s disease clinical trials update: October 2025

Major Breakthroughs and Emerging Therapies

The most clinically advanced strategy is huntingtin lowering: reducing production of the protein made by the mutant gene. AMT-130 is a one-time gene therapy in which an adeno-associated virus type 5 (AAV5) delivers an artificial microRNA into the striatum, a brain region heavily affected in HD, to lower HTT RNA. In September 2025, uniQure reported non-peer-reviewed topline results from its Phase I/II study: the high-dose group showed 75% slower decline on the composite Unified Huntington’s Disease Rating Scale (cUHDRS) at 36 months than a propensity-score-matched external control group. Because this was a small study using an external rather than concurrently randomized control, the result is encouraging but requires continued confirmation. uniQure AMT-130 Phase I/II topline results In June 2026, uniQure reported that the FDA had indicated that the three-year analysis could serve as the main basis for a planned accelerated-approval biologics license application, which the company intended to submit in the third quarter of 2026; this is not the same as FDA approval. uniQure AMT-130 regulatory update

A second gene-therapy program, SPK-10001, is testing a one-time AAV-delivered microRNA treatment injected into both the caudate and putamen. Unlike AMT-130’s initial study, its Phase I/II protocol includes a placebo-surgery-controlled portion, which may provide more rigorous evidence about clinical benefit and surgical risks. The Roche-sponsored trial is recruiting and plans to enroll up to 53 adults with early-stage HD. SPK-10001 Phase I/II trial

RNA-targeted medicines aim to reduce mHTT without permanently changing DNA. WVE-003 is an intrathecally administered antisense oligonucleotide (ASO), a short synthetic strand of nucleic acid designed to target an RNA molecule. It was designed to selectively lower the mutant copy of HTT in people who carry a suitable linked genetic marker, potentially preserving normal huntingtin; the completed Phase Ib/IIa SELECT-HD study enrolled 47 participants and posted results in 2025. SELECT-HD WVE-003 trial Tominersen, a non-allele-selective ASO developed by Roche and Ionis, remains an important cautionary lesson: in GENERATION HD2, Roche discontinued the higher 100 mg dose after an interim analysis, while modifying the study to continue evaluating the lower 60 mg dose. GENER­ATION HD2 trial Roche GENERATION HD2 community update

Oral medicines now offer another way to lower huntingtin. Votoplam, previously called PTC518, changes HTT RNA splicing so that the RNA is degraded before it can be translated into protein. In Phase II PIVOT-HD, PTC reported dose-dependent lowering of blood huntingtin at 12 weeks and exploratory signs consistent with clinical benefit in people with stage 2 disease, but these findings were preliminary and not yet definitive evidence of slowed progression. PTC518 PIVOT-HD Phase II results Novartis is now sponsoring the recruiting 770-participant Phase III INVEST-HD trial, which will compare votoplam with placebo for up to 36 months in early symptomatic HD. INVEST-HD votoplam Phase III trial SKY-0515 is another oral RNA-splicing modulator intended to lower both HTT and PMS1, a DNA-repair protein implicated in CAG-repeat expansion; its randomized Phase II/III FALCON-HD study is recruiting. FALCON-HD SKY-0515 Phase II/III trial

A major scientific shift has been recognition that the inherited CAG repeat can continue expanding in individual brain cells during life. In 2025, single-cell work in human HD brain tissue found that the repeat can expand dramatically in vulnerable striatal projection neurons and that neurons with very long expansions lose normal cellular identity and are depleted. Long somatic DNA-repeat expansion drives neurodegeneration in Huntington’s disease This has elevated DNA-repair proteins—especially MSH3 and PMS1—as therapeutic targets. In patient-derived striatal neurons, an MSH3-targeting ASO reduced MSH3 and stalled further CAG-repeat expansion, providing an important preclinical proof of concept rather than a human treatment result. MSH3 suppression reduces somatic CAG expansion

True gene editing remains preclinical. Researchers have used CRISPR-Cas9 systems to selectively disrupt mutant HTT through nearby single-nucleotide variants in mouse models, reducing mutant huntingtin while retaining the normal allele. Allele-specific CRISPR knockdown of mutant huntingtin Other mouse-model work used an engineered Cas9 enzyme to contract the expanded CAG tract itself and reported recovery of disease-related abnormalities in cells and animals derived from edited embryonic stem cells. Precise CAG-repeat contraction with SpCas9-NG These studies are scientifically significant, but safe delivery throughout the human brain, prevention of unintended edits, and proof of durable benefit remain unresolved.

Clinical Trials and Experimental Approaches

AMT-130 is the leading one-time gene-therapy program, with completed or ongoing Phase I/II studies in early manifest HD. The company’s 36-month high-dose analysis compared 12 treated participants with an external natural-history control group and reported statistically significant differences in cUHDRS and Total Functional Capacity; the small sample, absence of a concurrent randomized control group in that comparison, invasive brain surgery, and lack of a peer-reviewed full report mean that the result should be interpreted cautiously. uniQure AMT-130 Phase I/II topline results AMT-130 Phase I/II trial

The most consequential ongoing placebo-controlled studies are Novartis’s Phase III INVEST-HD trial of oral votoplam and Skyhawk’s Phase II/III FALCON-HD trial of SKY-0515. INVEST-HD is recruiting approximately 770 participants and measures clinical, biomarker, and safety outcomes over up to 36 months. INVEST-HD votoplam Phase III trial FALCON-HD is evaluating once-daily SKY-0515 across several dose levels against placebo. FALCON-HD SKY-0515 Phase II/III trial In parallel, Roche’s SPK-10001 and Wave’s WVE-003 illustrate two distinct experimental approaches—locally delivered, durable gene therapy and allele-selective intrathecal RNA treatment, respectively. SPK-10001 Phase I/II trial SELECT-HD WVE-003 trial

Methodologies and Scientific Approaches

HD researchers combine patient-derived induced pluripotent stem cells, engineered neurons, mouse models, nonhuman-primate delivery studies, and donated human brain tissue to test whether an intervention reaches vulnerable cells and changes the disease process. Modern studies increasingly measure mutant huntingtin in blood or cerebrospinal fluid, neurofilament light chain (NfL) as a marker of neuronal injury, MRI-based brain-volume changes, digital movement measures, and clinical composites such as cUHDRS and Total Functional Capacity. Huntington’s disease clinical trials update: October 2025 INVEST-HD votoplam Phase III trial

Large longitudinal datasets are also central to trial design. Enroll-HD is a multinational observational platform sponsored by CHDI Foundation that provides natural-history data, participant infrastructure, and biosamples for HD research; these resources can help identify trial participants and contextualize treatment effects, although external-control comparisons cannot fully replace well-designed randomized trials. Enroll-HD research platform Enroll-HD integrated clinical research platform

Leading Institutions and Funding

University College London’s Huntington’s Disease Centre, the University of Cambridge, the Broad Institute and Harvard-associated laboratories, and centers participating in the Huntington Study Group and European Huntington’s Disease Network are prominent academic contributors. Commercial developers include uniQure, Roche and Spark Therapeutics, Novartis, Wave Life Sciences, Skyhawk Therapeutics, Alnylam, Ionis, and Vico Therapeutics. Huntington’s disease clinical trials update: October 2025

CHDI Foundation is a major nonprofit driver of translational HD research and funds Enroll-HD, described as the world’s largest observational study for HD families. Enroll-HD research platform The Huntington’s Disease Society of America also supports investigator development and early-stage projects; for example, its Berman-Topper Family HD Career Development Fellowship provides up to $80,000 per year for young postdoctoral researchers. HDSA research funding programs

Strengths, Limitations, and Challenges

The field’s greatest strength is that several therapies now attack causal biology rather than only chorea or psychiatric symptoms. It also has multiple independent strategies—protein lowering, RNA modulation, somatic-expansion prevention, and gene therapy—so failure of one mechanism or delivery method does not end the broader search for disease modification. The move toward earlier-stage trials, biomarker-rich protocols, and placebo-controlled late-phase studies is particularly important because meaningful preservation of function may be easier before extensive neuronal loss has occurred. Huntington’s disease clinical trials update: October 2025

The central limitations are biological and practical. Normal huntingtin likely has important functions, so nonselective lowering must establish a safe long-term dose; allele-selective treatments may only work for people with particular linked genetic variants. Brain-directed gene therapies require specialized neurosurgery and may be difficult to reverse if adverse effects emerge. Biomarker reduction alone does not prove clinical benefit, as illustrated by the prior tominersen experience, and HD progresses slowly enough that trials need large samples and long follow-up. Roche GENERATION HD2 community update Allele-specific CRISPR knockdown of mutant huntingtin

Outlook and Future Directions

HD is closer than it was in 2020 to a disease-modifying therapy, but it is not yet close to a proven cure. The milestones to watch are whether AMT-130’s regulatory submission produces an approval decision and longer-term safety data; whether votoplam and SKY-0515 show placebo-controlled preservation of cognition, function, and motor ability; whether allele-selective ASOs can safely lower mutant huntingtin; and whether MSH3/PMS1-targeting programs can safely stop somatic expansion before irreversible neuronal loss. A durable cure would likely require not merely lowering toxic protein, but preserving or restoring brain function early enough and safely enough to change the lifelong course of disease. uniQure AMT-130 regulatory update MSH3 suppression reduces somatic CAG expansion

References

Don't see your disease? Request a report